A Phase 2b Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa
Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to establish the efficacy of 20 mg/day and 40 mg/day doses of
istradefylline for reducing the mean total hours of awake time per day spent in the OFF state
in patients with advanced Parkinson's disease (PD) treated with levodopa.
Phase:
Phase 2
Details
Lead Sponsor:
Kyowa Hakko Kirin Company, Limited Kyowa Kirin Co., Ltd.